A roundtable discussion, moderated by Brian Rini, MD, addressed considerations for clear versus nonclear cell kidney cancer, as well as recent data from ESMO 2023. Dr. Rini was joined by Tian Zhang, MD; David McDermott, MD; and Hans Hammers, MD. In the next segment of the roundtable series, the panel talks about nonclear cell kidney cancer, including treatment options and clinical trial data in this subgroup. ...
nccRCC
Advertisement
A Merit Award-winning abstract offered insight into differences in RCC susceptibility and implications for genetic screening.
While advances have improved understanding of molecular targets, optimal management of nccRCC remains unclear.
Black patients had a lower survival rate compared with White patients, and they experienced a sharp decline in survival.
As one of the most aggressive forms of kidney cancer, there is a need for new treatment strategies for RMC.
Drs. Rini and Plimack discuss "impressive" non-clear cell RCC data.
Drs. Lee and McKay discuss the latest data on KEYNOTE-B61 for first-line lenvatinib plus pembrolizumab for nccRCC.
The largest analysis of outcomes for patients with sarcomatoid or rhabdoid metastatic nccRCC treated with IO-based regimens.
Dr. Msaouel shares his journey to becoming a world expert in RMC and the clinical trial work he led to improve outcomes.
Dr. Rini provided an overview of nccRCC, including data pertaining to response to IO monotherapy and IO/TKI combinations.
The panel shares how they treat frontline papillary kidney cancer.
Advertisement
Conference Coverage
The retrospective analysis evaluated the data of patients who underwent multiagent chemotherapy.
At SUO 2023, Dr. Nicholas Corsi, UT Southwestern, presented one of the largest multinational studies on NAC in UTUC to date.
Almost half of all patients initiating 1L platinum-based chemotherapy were unable to receive maintenance avelumab treatment.
The generative AI model ChatGPT was fed a prostate cancer risk stratification algorithm.
The primary outcome was the potential for focal or hemi-gland ablation following analysis of the final pathologic specimen.
R-RPLND may offer lower morbidity and improved perioperative outcomes than O-RPLND for patients with CS II testicular cancer.
